2024
Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure
Krim S, Anand S, Greene S, Chen A, Wojdyla D, Vilaro J, Haught H, Herre J, Eisenstein E, Anstrom K, Pitt B, Velazquez E, Mentz R. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure. JAMA Cardiology 2024, 9: 182-188. PMID: 37955908, PMCID: PMC10644243, DOI: 10.1001/jamacardio.2023.4776.Peer-Reviewed Original ResearchDe novo heart failureNovo heart failureChronic heart failureHeart failurePatient-reported outcomesCause mortalityHF typeKansas City Cardiomyopathy Questionnaire clinical summary scoreHigher glomerular filtration rateSignificant differencesHeart Failure TrialGlomerular filtration rateClinical summary scoreDiuretic strategyFirst rehospitalizationCause hospitalizationNew onsetTotal hospitalizationsClinical characteristicsClinical profileEjection fractionLoop diureticsFailure TrialHospitalization outcomesNatriuretic peptide
2017
Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya
Temu TM, Lane KA, Shen C, Ng'ang'a L, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS, Bloomfield GS. Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. PLOS ONE 2017, 12: e0185204. PMID: 28934312, PMCID: PMC5608343, DOI: 10.1371/journal.pone.0185204.Peer-Reviewed Original ResearchConceptsValvular AFValvular heart diseaseAtrial fibrillationNVAF patientsAF patientsHeart diseaseNon-valvular atrial fibrillationGlobal cardiovascular disease burdenValvular atrial fibrillationRates of hypertensionCardiovascular disease burdenLong-term outcomesProspective data collectionAnticoagulation therapyClinical characteristicsCohort studyClinical profileHeart failureOverall mortalityClinical featuresComorbid conditionsFatal outcomeMean ageFemale sexDisease burden